Charles River, Cypre collaborate on in vitro services

By The Science Advisory Board staff writers

January 29, 2021 -- Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles River clients will have access to Cypre's 3D tumor model assay, Falcon-X, a move that expands Charles River's 3D in vitro testing services.

The Falcon-X 3D in vitro tumor assay is an analysis screening option for cancer immunotherapy and targeted therapy. Using Cypre's 3D hydrogel patterning technology Symphony and VersaGel, the assay recreates the tumor microenvironment and enables predictive screening of immuno-oncology compounds.

Charles River will have a new addition to Cypre's human oncology assay repertoire, allowing identification of therapeutics that overcome cancer immunotherapy resistance, the firms said. In addition, Cypre will be able to screen multiple therapeutic modalities alone or in combination using Charles River's genomically annotated and in vivo characterized cancer model database.

The database constitutes more than 700 tumor models, including patient-derived xenografts (PDX), cell lines, and cell line derived xenografts.

Charles River Laboratories acquires Distributed Bio
Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.
BioVaxys' COVID-19 vaccine may provide longer protection
BioVaxys Technology has released data about its haptenized viral protein vaccine technology used in BVX-0320, its COVID-19 vaccine candidate. The candidate...
BioVaxys' COVID-19 vaccine shows positive early results
BioVaxys Technology has announced its SARS-CoV-2 vaccine had a 96.4% positive antibody immune response, according to results from a preclinical animal...
LabShares Newton offers free space for COVID-19 research
LabShares Newton is offering free, fully equipped biosafety level 2 lab space, facilities, and resources for researchers addressing the global COVID-19...
Charles River, Deciphex form digital pathology partnership
Charles River Laboratories has entered into a partnership with software firm Deciphex to offer a digital pathology workflow platform.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter